Complement Factor H Knock Out Mouse Model

Reference number 2533

Sectors: Pharmaceuticals

Industries: Biotechnology

Proposed use

This disease model is useful for conditions in which complement factor H plays a role.

Target market: SMEs and larger multi-nationals working on preclinical targeting of AMD; Research groups interested in targeting complement factor H.

Problem addressed

In the field of eye disease, such as age-related macular degeneration (AMD) this mouse model has been proven important for research into the mechanisms of disease. With the evolving field of gene therapy, the model is also suitable for pre-clinical evaluation of gene therapy for AMD as Genome Wide Association Studies (GWAS) have encountered an association between AMD and a variation of the gene encoding complement factor H.

Benefits

  • Complement proteins within drusen
  • Association between AMD and mutations in various complement pathway genes, most notably complement factor H

Technology overview

Complement factor H is an important contributor to Age-related Macular Degeneration (AMD), a leading cause of blindness worldwide. In SNP studies, an intronic and common variant in the complement factor H gene is strongly associated with AMD. In individuals homozygous for the risk allele, the likelihood of AMD is increased by a factor of 7.4. Thus, the complement system has featured as a unifying theme for several elements of novel evidence in AMD:

  1. The discovery that the complement proteins within drusen; and
  2. The association between AMD and mutations in various complement pathway genes, most notably complement factor H.

The importance of drusen extracellular material in association with factor H implies that this model could be relevant for other diseases such as atherosclerosis, elastosis, amyloidosis and dense deposit disease.

Current management of yAMD focuses on VEGF therapy where new vessel growth has been the primary target; however, this approach does not address the underlying disease pathology. This disease model is useful for conditions in which complement factor H plays a role.

Intellectual Property Information

Reagent/material

Research Paper

Pickering et al., Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

Inventor

Professor Marina Botto

Head of Department, Director of Bioservices
Faculty of Medicine, Department of Immunology and Inflammation

Visit personal site

Contact us about this technology



Contact

Dr Emily Allen-Benton

Industry Partnerships and Commercialisation Officer, Medicine

Emily is an IPC Officer within the Faculty of Medicine team focussed on intellectual property management, supporting Imperial academics with commercial engagement, fostering collaborative research and negotiating out-licenses. Emily manages an IP portfolio which included the Faculty of Medicine Quicktech portfolio, comprising mouse models and other research tools. Emily holds a PhD in Chemistry focussed […]

Contact Emily

e.allen-benton@imperial.ac.uk

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...